Protalix BioTherapeutics, Inc. (PLX)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$2.67+1.91%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Protalix aims for $78M to $83M revenue in 2026. Revenue grew from $9.1M in 2025-Q4 to $33.8M in 2026-Q1. The company is cheap with a PE of 16.9 versus peers at 21.7. Management is stable and momentum is rising.
Revenue could fall below $78M in 2026. Milestone payments from Chiesi may not happen. The company faces elevated risk and fragile quality.
The price is about 12% below our fair value near $2.68. Analysts expect about 8% revenue decline, but we see growth to $80.5M in 2026.
Breaks if: Major management turnover or instability occurs
Breaks if: Milestone payment not secured by end of FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on growth in the healthcare sector. The current thesis remains intact, supported by strong financial performance and management priorities.
The market currently prices PLX as cheap compared to its peers, reflecting a justified valuation. There is an expectations gap, indicating that the market may not fully account for potential upside from recent performance and sector momentum.
Fundamentals are likely to continue improving, driven by management's focus on achieving revenue guidance and advancing clinical trials. However, there is a near-term risk of missing earnings expectations, which could impact sentiment.
The long-term thesis hinges on maintaining revenue growth and successful advancements in clinical trials. Additionally, the performance of sector leaders and overall economic conditions will play a critical role in shaping future outcomes.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the company's growth objectives. However, there are market concerns about achieving the 2026 revenue guidance of $78M-$83M.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Achieve and recognize the $25 million milestone payment from Chiesi related to Elfabrio regulatory approval.
Stated as a priority in 2 of last 3 quarters. The $25 million milestone payment from Chiesi was received and recognized in Q1 2026, contributing significantly to revenue growth. Management has incorporated this milestone into 2026 revenue guidance. The milestone has been secured and delivered as planned.
“The Company received a $25 million milestone payment from Chiesi related to the E4W dosage approval in the EU.”
“Management expects total revenues in 2026 to include the $25 million milestone payment from Chiesi.”
Breaks if: Revenue falls below $78 million in FY26
Deliver full-year 2026 total revenue between $78.0 million and $83.0 million including the $25 million milestone from Chiesi.
Stated as a priority in 3 of last 3 quarters. Total revenue grew from $25.8 million in first half of 2025 to $53.6 million in first half of 2026, including a $25 million milestone from Chiesi. Management has consistently reaffirmed the 2026 revenue guidance range of $78.0 million to $83.0 million, and the trajectory is delivering toward this target.
“The Company reiterates full-year 2026 guidance of $78.0 million to $83.0 million in total revenue including the $25.0 million milestone received from Chiesi.”
“The Company reaffirms its previously stated 2026 revenue guidance of $78.0-$83.0 million including the $25.0 million milestone received from Chiesi.”
“Based on current estimates, management expects total revenues in 2026 to range from approximately $78.0 million to $83.0 million including the $25.0 million payment referenced above.”
Overall, the outlook for PLX is cautiously optimistic, with strong management execution needed to navigate potential risks. Not investment advice.